Donald Fink, Ph.D.

Prior to joining Dark Horse Consulting Group, Don provided 33+ years of uninterrupted service to the United States Federal government, first as a Pharmacology Research Associate Fellow at the National Institutes of Health followed by over 27 years at the FDA Center for Biologics Evaluation and Research (CBER). While at FDA/CBER, Don served as the CMC reviewer for over 100 files submitted by Sponsors that included INDs, IDEs, 510(k)s, BLAs and a PMA for products ranging from recombinant therapeutic proteins, biologic cellular therapies, and cellular combination products.

Most recently, Don was an Expert Biologist in FDA/CBER’s Office of Tissues and Advanced Therapies (OTAT), Division of Cellular and Gene Therapies, Cell Therapy Branch where he was engaged in regulatory activities pertaining to investigational cellular products comprised or derived from starting populations of stem/progenitor cells. Don was responsible for CMC oversight of an extensive portfolio of applications that included hematopoietic, mesenchymal, cord blood, placenta, and pluripotent (hESC and induced pluripotent)-derived stem cell therapeutic products.

During his distinguished FDA career, Don organized an FDA advisory committee to address what at the time was the nascent topic of cellular replacement therapies for neurological disorders. The meeting had, as its focus, stem cell-based investigational products. He was also involved with the planning committee for an NIH/FDA co-sponsored workshop highlighting pluripotent stem cell (PSC)-based products in clinical translation. Don established and served as coordinator for an interest group that monitors development of investigational cellular products derived from PSCs giving attention to evolving issues of concern such as the accumulation of mutations during cellular replication that could impact the product safety profile. Don has served as FDA liaison to both the NIH Stem Cell Task Force and the International Society for Stem Cell Research (ISSCR) Task Force for Clinical Translation of Stem Cells. In 2002 Don co-founded and has co-chaired (through 2020) an FDA-NIH interagency working group in partnership with extramural program officers from the National Institute of Neurological Disorders and Stroke that promotes cross-agency dialogue to facilitate clinical translation of cellular and gene transfer-based products.

In addition to his skills as an FDA reviewer of cellular-based products, Don is recognized for his communication capability and knowledge sharing. He has trained and mentored FDA professional staff as well as served on the steering committee and as a faculty member for FDA’s Clinical Investigator Training Course which provides external stakeholders with in-depth information concerning FDA regulations, ethical considerations, and scientific principles that focus on what is important when conducting clinical trials and preparing submissions for FDA review. Don has given numerous outreach presentations and authored or co-authored several book chapters that outline FDA’s approach for the evaluation of stem cell-based therapies.